New data strengthening the continued clinical development of NeuroRestore ACD856

Alze­Cure Phar­ma, a phar­ma­ceu­ti­cal com­pa­ny that devel­ops a broad port­fo­lio of small mol­e­cule can­di­date drugs for dis­eases affect­ing the cen­tral ner­vous sys­tem, with projects in both Alzheimer’s dis­ease and pain, today announced that the com­pa­ny’s pre­sen­ta­tions at the sci­en­tif­ic con­fer­ence CTAD 2022 are now avail­able in their entire­ty on Alze­Cure’s web­site. They include new clin­i­cal and pre­clin­i­cal data with the company’s lead­ing drug can­di­date Neu­roRe­store ACD856, which is being devel­oped with a focus on Alzheimer’s disease

The abstracts, titled Quan­ti­ta­tive EEG results from a mul­ti­ple ascend­ing dose study in healthy vol­un­teers with Neu­roRe­store ACD856, a pos­i­tive mod­u­la­tor of Neu­rotrophin Trk-recep­tors, and Pre­clin­i­cal char­ac­ter­i­za­tion of ACD856, a cog­ni­tive enhancer in clin­i­cal devel­op­ment for the treat­ment of cog­ni­tive dys­func­tion in Alzheimer’s dis­ease, demon­strates increased plas­tic­i­ty, neu­ro­pro­tec­tion and a pos­si­ble dis­ease mod­i­fy­ing effect, were pre­sent­ed by Johan Sandin, CSO, and Mar­tin Jöns­son, CEO at Alze­Cure Phar­ma. The results include new clin­i­cal and pre­clin­i­cal data with ACD856, the lead drug can­di­date in the Neu­roRe­store project.

The clin­i­cal data come from the recent­ly com­plet­ed phase I MAD study, where the sub­stance, in addi­tion to good safe­ty and tol­er­a­bil­i­ty, was also shown to cross the blood-brain bar­ri­er effec­tive­ly and in rel­e­vant quan­ti­ties. The new EEG data, which mea­sures brain activ­i­ty, also showed that ACD856 acti­vates rel­e­vant neu­ronal path­ways in the brain with rel­e­vance for cog­ni­tion and depres­sion, some­thing that strength­ens the con­tin­ued clin­i­cal devel­op­ment of the substance.

In addi­tion to mem­o­ry-enhanc­ing and symp­tom-reliev­ing prop­er­ties, the pre­clin­i­cal data pre­sent­ed show that ACD856, also has poten­tial­ly dis­ease-mod­i­fy­ing prop­er­ties with both neu­rorestora­tive and neu­ro­pro­tec­tive prop­er­ties. The sub­stance also shows pos­i­tive long-term effects after repeat­ed admin­is­tra­tion, which indi­cates an enhanced plas­tic­i­ty in rel­e­vant neu­ronal pathways.

A pos­i­tive mod­u­la­tor of both NGF/Tr­kA- and BDNF/TrkB-medi­at­ed sig­nal­ing, ACD856 has been shown in pre­clin­i­cal stud­ies to improve cog­ni­tion and mem­o­ry and is poised for Phase 2 clin­i­cal tri­als, where it is being devel­oped pri­mar­i­ly for the treat­ment of Alzheimer’s disease.

“These new pos­i­tive results with ACD856 sup­port the con­tin­ued clin­i­cal devel­op­ment of the sub­stance in both cog­ni­tive dis­or­ders and depres­sion. The fact that we also see neu­ro­pro­tec­tive effects of the sub­stance is some­thing that can fur­ther strength­en exter­nal inter­est in the project,” said Johan Sandin, CSO at Alze­Cure Pharma.

“This is very good news and devel­op­ment that adds to the pre­vi­ous pos­i­tive data for ACD856 and fur­ther strength­ens our com­mer­cial oppor­tu­ni­ties for this promis­ing com­pound,” said Mar­tin Jöns­son, CEO of Alze­Cure Phar­ma AB.